Paper Details

  1. Home
  2. Paper Details

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

Author: Andrade-VillanuevaJaime-Federico, BaumgartenAxel, BredeekFritz, CahnPedro, ChountaVasiliki, CrauwelsHerta, FordSusan L, HarringtonConn M, HuangJenny, HudsonKrischan J, KimYeon-Sook, LatiffGulam, MargolisDavid A, MasiáMar, MrusJoseph, ParysWim, PatelParul, PokrovskyVadim, RichmondGary J, RizzardiniGiuliano, SmithGraham, SmithKimberly Y, SpreenWilliam R, SwindellsSusan, TalaricoChristine L, VanveggelSimon, WilliamsPeter E

Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that monthly injections of long-acting cabotegravir and rilpivirine were noninferior to standard oral therapy for maintaining HIV-1 suppression. While injection-related adverse events were common, they only infrequently led to medication withdrawal.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. METHODS: In this phase 3, open-label, multicenter, noninferiority trial involving patients who had had plasma HIV-1 RNA levels of le...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1904398

データ提供：米国国立医学図書館（NLM）

Simplifying HIV Treatment: Long-Acting Cabotegravir and Rilpivirine

HIV treatment has come a long way, but adherence to daily medication regimens can be challenging. This research explores the efficacy and safety of long-acting cabotegravir and rilpivirine, administered as monthly intramuscular injections, in maintaining HIV suppression. The study found that this long-acting therapy was noninferior to standard oral therapy in maintaining HIV-1 suppression, offering a potentially more convenient and user-friendly treatment option for patients.

A New Era of HIV Treatment

This study suggests a promising new era in HIV treatment, offering a simpler and potentially more convenient approach for patients. The long-acting therapy proved noninferior to oral therapy in suppressing HIV-1, demonstrating its effectiveness in managing this complex condition.

Empowering Patients with Choice

The availability of long-acting therapy provides patients with more options to choose from based on their individual needs and preferences. This approach empowers patients to participate more actively in their treatment, leading to potentially improved adherence and better overall health outcomes.

Dr. Camel's Conclusion

Just as a camel can travel long distances in the desert, managing HIV requires a sustained and consistent approach. This research highlights the promise of long-acting therapy, offering a potentially more convenient and user-friendly option for maintaining HIV suppression. Remember, open communication with your healthcare provider is key to finding the treatment approach that best suits your individual needs and preferences.
Date :
  1. Date Completed 2020-03-25
  2. Date Revised 2020-11-25
Further Info :

Pubmed ID

32130809

DOI: Digital Object Identifier

10.1056/NEJMoa1904398

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.